Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001

Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001

Item

http://www.wikidata.org/entity/Q30452998

Q30452998

about

The trend of susceptibilities to amphotericin B and fluconazole of Candida species from 1999 to 2002 in Taiwan.Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing.Comparison of results of fluconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program.Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole Evaluation of Etest and disk diffusion methods compared with broth microdilution antifungal susceptibility testing of clinical isolates of Candida spp. against posaconazole.Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit.Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases.Agar-based disk diffusion assay for susceptibility testing of dermatophytes.In vitro susceptibility testing of Geotrichum capitatum: comparison of the E-test, disk diffusion, and Sensititre colorimetric methods with the NCCLS M27-A2 broth microdilution reference method.Canadian clinical practice guidelines for invasive candidiasis in adults.Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.Fungal infections in burns: Diagnosis and management Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003).Candida parapsilosis, an emerging fungal pathogen Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature.Antifungal activity of amphotericin B and voriconazole against the biofilms and biofilm-dispersed cells of Candida albicans employing a newly developed in vitro pharmacokinetic model.Evaluation of the NCCLS M44-P disk diffusion method for determining susceptibilities of 276 clinical isolates of Cryptococcus neoformans to fluconazole Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents.Stability of Mueller-Hinton agar supplemented with glucose and methylene blue for disk diffusion testing of fluconazole and voriconazole.Endogenous Candida endophthalmitis.Comparison of Enzymatic Method Rapid Yeast Plus System with RFLP-PCR for Identification of Isolated Yeast from Vulvovaginal Candidiasis Nosocomial fungal infections: epidemiology, diagnosis, and treatment.Host factors do not influence the colonization or infection by fluconazole resistant Candida species in hospitalized patients Microdilution in vitro Antifungal Susceptibility Patterns of Candida Species, From Mild Cutaneous to Bloodstream Infections.Quality control limits for voriconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue.Candiduria: prevalence and trends in antifungal susceptibility in a tertiary care hospital of mangalore.Yeast identification algorithm based on use of the Vitek MS system selectively supplemented with ribosomal DNA sequencing: proposal of a reference assay for invasive fungal surveillance programs in China.CaNdt80 is involved in drug resistance in Candida albicans by regulating CDR1 A single center's experience with Candida parapsilosis related long-term central venous access device infections: the port removal decision and its outcomes.Whole Genome Sequence of the Heterozygous Clinical Isolate Candida krusei 81-B-5.Species distribution and susceptibility profile of Candida species in a Brazilian public tertiary hospital.In vitro activity of five antifungal agents against Candida albicans isolates, Sari, Iran Development of novel real-time PCR assays for detection and differentiation of eleven medically important Aspergillus and Candida species in clinical specimens.Rapid, high-throughput, multiplex, real-time PCR for identification of mutations in the cyp51A gene of Aspergillus fumigatus that confer resistance to itraconazole Nosocomial candidiasis in Rio de Janeiro State: Distribution and fluconazole susceptibility profile.Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis.Caspofungin Etest endpoint for Aspergillus isolates shows poor agreement with the reference minimum effective concentration.

P2860

Q24814052-97BAC289-9E79-480E-8499-3B9CF1E348CE Q30311996-2C436F14-8A09-418A-8003-1B6EE36D38B0 Q30447051-4050FD85-ACBF-4339-82A1-1253E017C1EE Q30449026-257B23CD-8033-46BC-AA8A-084372750B6B Q30452973-A82B4BDC-ABA8-47A5-9CA4-4DB9FC1351C9 Q33273842-58699CAC-32F6-45D4-B67D-304EE367E20B Q33774225-A341071D-9269-45F3-B9EC-6D948A244357 Q33856434-6C056ECC-3448-43D6-9321-18F8F27DE3E0 Q33859133-E67FF89E-3DFE-4280-A417-FFF043CEA213 Q34190254-42474505-954D-4924-8115-D97A75B421C3 Q34231270-F4674295-4600-4E7F-BCFC-F35B6C2C9331 Q34237335-3D06DE50-68D9-42CE-A080-62ADCB8DE127 Q34431984-A34AB9CD-A847-464F-9781-24CC4BBEDE12 Q34571473-66D21F46-D09A-4BB5-AC90-BD902C91D737 Q34647337-B946C31A-9BCB-4E11-B331-3981FBB5A5C6 Q34680831-13E498E4-8A9E-4D76-BF8E-BF73E50B9F44 Q34852747-3F73E56A-879E-4491-8DC8-C5BFC0CB6056 Q34937478-9602EBAF-DFC3-40F3-B4F0-952B8A7CD4FB Q35318531-7E079BA4-A090-487A-8C22-78DAB7346E32 Q35552662-89B32FB5-8263-49E6-A8A8-EEDC766AEB65 Q36505508-A6F2E546-438C-4E81-A83B-65315F7FE984 Q36600457-DA1718D4-E361-4056-BF3D-885588444582 Q36607424-3E781FD6-3073-4CB0-A9AE-36A9BC7E2144 Q36652486-14C93A40-82B5-4DEE-A5A0-574CAD53DB36 Q36825717-596BCBE5-B55E-4587-B611-8686C3442001 Q37052163-EA1F8947-4645-411A-93D1-C03145622B8E Q37280669-24115D3D-1028-453F-8B1E-CB140EE29D20 Q37420895-A092051D-C98E-4AB1-ADF4-D0A0FF02108B Q37429646-869DF051-2FC5-4B99-B81B-55E1F3461411 Q37546287-793B2CE4-C0EF-4E38-92DC-E6D7BFEAA2FA Q37625361-0752BDEF-DE79-4399-87F1-5EC569E4AFE4 Q38175195-113A8A40-CCDA-48E6-B390-4A1D9FC85048 Q38684199-9A1B54FA-501E-49AA-AA0F-ADB8FA45EA53 Q39361000-E7FF61E8-9436-44C4-BE84-076DD248EB8E Q39459173-817E8982-D808-48A4-86AD-89CEA61AFB53 Q40248979-BC6D3283-A429-41CE-A97D-FD1A93F7C7EA Q40771905-77B89DF4-B4B4-46D9-93B5-8B9FFDABFB9F Q41052448-56CD3DB6-C339-4BA0-ADB9-CA27C6AED866 Q41838145-EDAD262B-48DA-4C41-80DB-0833686CFA91 Q41938809-F93C43AC-2FB7-41A8-B305-102A7BFB816B

P2860

Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001

Item

http://www.wikidata.org/entity/Q30452998

description

2003 nî lūn-bûn

@nan

2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu